Punam Malik, MD
Title
Program Leader, Molecular and Gene Therapy Program; Deputy Director, Comprehensive Sickle Cell Program
Appointment
Associate Professor of Pediatrics
Email
punam.malik@cchmc.org
Phone
513-636-1333
Fax
513-636-1330
Credentials
MBBS: University of Delhi, New Delhi, India, 1985
MD: University of Delhi, New Delhi, India, 1989
MS: University of Maryland, Baltimore, MD., 1991
Fellowship: [Hematology-Oncology]: Children's Hospital Los Angeles, University of Sourthern California, 1995
Awards and Honors
- National Talent Scholar, National Council for Education, Research and Training, 1978-1987
- Proficiency in Medicine Award, 1984
- Best III Year Resident Award, 1987
- CHLA Research Fellowship Award, 1993
- Concern Foundation Fellow, 1993-1996
- Scholar, Comprehensive Sickle Cell Center, 1998-2003
- Research Career Development Award, CHLA, 2000-2002
- Wright Foundation Fellow, 2003-2004
- Editorial Board Member, Experimental Hematology, 2003-2005
- Editorial Board, Member. Blood, 2005-2007
- Outstanding New Investigator Award, 9th Annual Meeting of the American Society of Gene Therapy, 2006
- National Sickle Cell Advisory Committee Member, 2006
Research Grants and Contracts
R01 HL70135 (Malik) 04/01/02-03/31/08 NIH-NHLBI Lentiviral vectors for gene therapy for B-thalassemia
P01 HL0731404 (Kohn) 04/01/03-03/31/08 NIH-NHLBI Gene Therapy for Hematopoietic Disorders
Project Leader (Malik) Minimal lentiviral vectors for gene therapy for B-thalassemia
U54 HL070595 (Joiner, C) 04/01/03-03/31/08 NIH-NHLBI
Comprehensive Sickle Cell Center
R01 HL079916 (Malik) 07/01/05-06/31/09 NIH-NHLBI Role of placenta growth factor in sickle acute chest syndrome
Publications, Most Recent
Connect to Punam Malik's publications on PubMed
Moreau-Gaudry F, Xia P, Jiang G, Perelman NP, Bauer G, Ellis J, Surinya KH, Mavilio F, Shen CK, Malik P. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors.Blood. 2001 Nov 1;98(9):2664-2672.
Richard E, Mendez M, Mazurier F, Morel C, Costet P, Xia P, Fontanellas A, Geronimi F, Cario-Andre M, Taine L, Ged C, Malik P, de Verneuil H, Moreau-Gaudry F. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection.Mol Ther. 2001 Oct;4(4):331-338.
Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD, Kalra VK, Malik P. Placenta growth factor activates monocytes and correlates with sickle cell disease severity.Blood. 2003 Aug 15;102(4):1506-1514.
Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor.Blood. 2003 Aug 15;102(4):1515-1524.
Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival.Lab Invest. 2003 Oct;83(10):1477-1487.
Luck L, Zeng L, Hiti AL, Weinberg KI, Malik P. Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells.Exp Hematol. 2004 May;32(5):483-493.
Mohamedali A, Moreau-Gaudry F, Richard E, Xia P, Nolta J, Malik P. Self-inactivating lentiviral vectors resist proviral methylation but do not confer position-independent expression in hematopoietic stem cells.Mol Ther. 2004 Aug;10(2):249-259.
Puthenveetil G, Scholes J, Carbonell D, Qureshi N, Xia P, Zeng L, Li S, Yu Y, Hiti AL, Yee JK, Malik P. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.Blood. 2004 Dec 1;104(12):3445-3453.
Madigan C, Malik P. Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease.Expert Rev Mol Med. 2006 8(9):1-23.
Urbinati F, Madigan C, Malik P. Pathophysiology and therapy for haemoglobinopathies; Part II: thalassaemias.Expert Rev Mol Med. 2006 8(10):1-26.
Robert-Richard E, Richard E, Malik P, Ged C, de Verneuil H, Moreau-Gaudry F. Murine Retroviral but not Human Cellular Promoters Induce In Vivo Erythroid-specific Deregulation that can be Partially Prevented by Insulators.Mol Ther. 2007 Jan;15(1):173-182.
Cheng JC, Horwitz EM, Karsten SL, Shoemaker L, Kornblum HI, Malik P, Sakamoto KM. Report on the workshop "New Technologies in Stem Cell Research," Society for Pediatric Research, San Francisco, California, April 29, 2006.Stem Cells. 2007 Apr;25(4):1070-1088.
